The first 2 months of the SARS-CoV-2 epidemic in Yemen: Analysis of the surveillance data.
Adolescent
Adult
Aged
Aged, 80 and over
Betacoronavirus
COVID-19
Child
Child, Preschool
Comorbidity
Contact Tracing
Coronavirus Infections
/ epidemiology
Epidemiological Monitoring
Female
Humans
Infant
Infant, Newborn
Male
Middle Aged
Pandemics
Pneumonia, Viral
/ epidemiology
SARS-CoV-2
Yemen
/ epidemiology
Young Adult
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
28
07
2020
accepted:
12
10
2020
entrez:
29
10
2020
pubmed:
30
10
2020
medline:
11
11
2020
Statut:
epublish
Résumé
Yemen was one of the last countries in the world to declare the first case of the pandemic, on 10 April 2020. Fear and concerns of catastrophic outcomes of the epidemic in Yemen were immediately raised, as the country is facing a complex humanitarian crisis. The purpose of this report is to describe the epidemiological situation in Yemen during the first 2 months of the SARS-CoV-2 epidemic. We analyzed the epidemiological data from 18 February to 05 June 2020, including the 2 months before the confirmation of the first case. We included in our analysis the data from 10 out of 23 governorates of Yemen, located in southern and eastern part of the country. A total of 469 laboratory confirmed, 552 probable and 55 suspected cases with onset of symptoms between 18 February and 5 June 2020 were reported through the surveillance system. The median age among confirmed cases was 46 years (range: 1-90 years), and 75% of the confirmed cases were male. A total of 111 deaths were reported among those with confirmed infection. The mean age among those who died was 53 years (range: 14-88 years), with 63% of deaths (n = 70) occurring in individuals under the age 60 years. A total of 268 individuals with confirmed SARS-CoV-2 infection were hospitalized (57%), among whom there were 95 in-hospital deaths. The surveillance strategy implemented in the first 2 months of the SARS CoV 2 in the southern and eastern governorates of Yemen, captured mainly severe cases. The mild and moderate cases were not self-reported to the health facilities and surveillance system due to limited resources, stigma, and other barriers. The mortality appeared to be higher in individuals aged under 60 years, and most fatalities occurred in individuals who were in critical condition when they reached the health facilities. It is unclear whether the presence of other acute comorbidities contributed to the high death rate among SARS-CoV-2 cases. The findings only include the southern and eastern part of the country, which is home to 31% of the total population of Yemen, as the data from the northern part of the country was inaccessible for analysis. This makes our results not generalizable to the rest of the country.
Identifiants
pubmed: 33119720
doi: 10.1371/journal.pone.0241260
pii: PONE-D-20-23480
pmc: PMC7595428
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0241260Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Lancet Respir Med. 2020 Apr;8(4):420-422
pubmed: 32085846
Lancet. 2020 May 30;395(10238):1683
pubmed: 32473668
Soc Sci Med. 1983;17(12):783-93
pubmed: 6879237
Pan Afr Med J. 2019 May 28;33(Suppl 2):3
pubmed: 31404272
Int J Infect Dis. 2020 May;94:128-132
pubmed: 32251805
Nat Commun. 2020 Jul 1;11(1):3280
pubmed: 32612128
Int J Environ Res Public Health. 2007 Sep;4(3):243-7
pubmed: 17911664
J Autoimmun. 2020 May;109:102433
pubmed: 32113704
J Med Virol. 2020 Jun;92(6):548-551
pubmed: 32096567
Pathogens. 2020 Mar 20;9(3):
pubmed: 32245083
Lancet Infect Dis. 2020 Sep;20(9):1015-1016
pubmed: 32304629
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
PLoS Curr. 2017 Nov 9;9:
pubmed: 29188127
J Bone Joint Surg Am. 2020 May 6;102(9):734-744
pubmed: 32379112
J Gen Intern Med. 2020 May;35(5):1545-1549
pubmed: 32133578
Ann Saudi Med. 2002 Jan-Mar;22(1-2):34-7
pubmed: 17259764
Lancet Infect Dis. 2020 Jul;20(7):776-777
pubmed: 32224313
J Intensive Care Soc. 2018 Nov;19(4):319-325
pubmed: 30515241
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Travel Med Infect Dis. 2020 Sep - Oct;37:101652
pubmed: 32247929
Lancet Glob Health. 2020 Apr;8(4):e480
pubmed: 32109372
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
J Allergy Clin Immunol. 2020 Jul;146(1):110-118
pubmed: 32294485
Model Earth Syst Environ. 2020 Jun 17;:1-9
pubmed: 32838021
Int J Equity Health. 2020 Mar 21;19(1):41
pubmed: 32199457
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2004 Jul;148(1):11-5
pubmed: 15523540
Infect Control Hosp Epidemiol. 2020 Jun;41(6):754-755
pubmed: 32192541
Eur Respir J. 2020 May 14;55(5):
pubmed: 32217650
Nat Med. 2020 Apr;26(4):506-510
pubmed: 32284616
J Clin Virol. 2020 Jun;127:104378
pubmed: 32353762
J R Soc Med. 1987 Dec;80(12):762-5
pubmed: 3323513
Immunity. 2020 Apr 14;52(4):583-589
pubmed: 32259480